Eswatini vs Least developed countries: Antiretroviral therapy coverage
Eswatini
94.0%
in 2024
Least developed countries
82.5%
in 2024
Eswatini rank
7th
Least developed countries rank
10th
Antiretroviral therapy coverage over time
- Eswatini
- Least developed countries
How they compare
Eswatini currently reports 94.0% against 82.5% in Least developed countries, a difference of 11.5%.
That makes Eswatini's figure about 1.1 times Least developed countries's.
The two have swapped places 1 time across 25 shared years of data; in 2000 it was Least developed countries ahead.
Eswatini ranks 7th and Least developed countries ranks 10th of 143 countries.
Eswatini has averaged higher in every one of the 3 decades both report.
Head to head by decade
| Decade | Eswatini | Least developed countries | Difference | Ahead |
|---|---|---|---|---|
| 2000s | 7.5% | 5.3% | 2.2% | Eswatini |
| 2010s | 58.2% | 43.0% | 15.2% | Eswatini |
| 2020s | 90.4% | 75.5% | 14.9% | Eswatini |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher antiretroviral therapy coverage, Eswatini or Least developed countries?
- Eswatini, at 94.0% against 82.5% in Least developed countries as of 2024.
- What is the difference in antiretroviral therapy coverage between Eswatini and Least developed countries?
- 11.5%, with Eswatini ahead.
- How many years of comparable data are there for Eswatini and Least developed countries?
- 25 years are reported by both, from 2000 to 2024.
- How do Eswatini and Least developed countries rank globally for antiretroviral therapy coverage?
- Eswatini ranks 7th and Least developed countries ranks 10th of 143 countries.
- Where does this data come from?
- UNAIDS estimates, Joint United Nations Programme on HIV/AIDS (UNAIDS), published as Antiretroviral therapy coverage (% of people living with HIV). Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Antiretroviral therapy coverage indicates the percentage of all people living with HIV who are receiving antiretroviral therapy.